France Expands National Compassionate Access for Agenus' Botensilimab/Balstilimab Combination to Include Ovarian Cancer and Soft-Tissue Sarcomas
核心洞察
France's National Agency for Medicines and Health Products Safety (ANSM (搜索)) has expanded its Autorisation d'Accès Compassionnel (AAC) framework to include ovarian cancer (搜索) and soft-tissue sarcomas (搜索) for the investigational immunotherapy combination botensilimab plus balstilimab.
The updated authorization extends fully reimbursed hospital-based access beyond refractory microsatellite-stable colorectal cancer (搜索), creating a multi-tumor early access framework under one nationally standardized protocol.
This represents an uncommon level of national early-access authorization that enables consistent hospital access while maintaining ANSM (搜索) oversight and structured patient follow-up as clinical evidence continues to develop.
France's National Agency for Medicines and Health Products Safety (ANSM (搜索)) has approved an expanded national protocol under the Autorisation d'Accès Compassionnel (AAC) framework for the investigational immunotherapy combination botensilimab (BOT) plus balstilimab (BAL), developed by Agenus Inc (搜索). The updated authorization, announced on January 12, 2026, broadens eligibility beyond refractory microsatellite-stable (MSS) colorectal cancer (搜索) to include selected ovarian cancers and soft-tissue sarcomas (搜索).
Expanded Treatment Access Under AAC Framework
The revised AAC protocol now authorizes reimbursed access to BOT/BAL for eligible adult patients with three distinct cancer types. For MSS metastatic colorectal cancer (搜索) without active liver metastases, patients must have progressed on standard therapies. The authorization also covers platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (搜索) after approved options have been exhausted. Additionally, patients with advanced or metastatic soft-tissue sarcomas (搜索), including multiple high-grade histologies, are eligible after failure of standard treatments.
Under the AAC program, treatment is fully reimbursed by France's national health system (Assurance Maladie), with standardized hospital oversight and structured real-world data collection. Reimbursement is structured as a single, upfront, course-based payment per patient that covers the patient's full course of therapy according to the national AAC protocol, rather than on a per-dose basis.
Novel Immunotherapy Mechanism of Action
Botensilimab is a human Fc-enhanced multifunctional anti-CTLA-4 (搜索) antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to "cold" tumors which generally respond poorly to standard of care or are refractory to conventional PD-1 (搜索)/CTLA-4 therapies. The antibody augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses.
Balstilimab is a fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (搜索) (programmed cell death protein 1) from interacting with its ligands PD-L1 (搜索) and PD-L2 (搜索). Together, BOT and BAL are designed to deliver synergistic immune activation, broadening the reach of checkpoint immunotherapy across resistant tumor microenvironments.
Clinical Development and Patient Experience
Approximately 1,200 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials, while balstilimab has been evaluated in more than 900 patients to date. The combination has demonstrated clinical activity and a favorable tolerability profile in several tumor types, with signals of durable benefit observed in multiple solid tumors.
Across clinical studies conducted to date, BOT/BAL has demonstrated antitumor activity in heavily pretreated populations, including tumor types with historically limited responsiveness to standard PD-1 (搜索)–based approaches. The AAC expansion reflects growing confidence in the combination's biologic rationale, emerging efficacy signals, and manageable safety profile.
Regulatory Status and Global Access
BOT/BAL remains investigational and is not approved for commercial marketing in France or elsewhere. Until marketing authorization is granted, the combination is accessible only through clinical trials including the Phase 3 BATTMAN trial in refractory MSS colorectal cancer (搜索) and authorized early access mechanisms where permitted and available under each country's regulatory framework.
Outside France, access may be available in select countries through paid named-patient programs, which may involve out-of-pocket payment and/or special insurance arrangements depending on local regulations and individual coverage decisions. In France, botensilimab and balstilimab are accessible only through the ANSM (搜索)-authorized AAC framework when used as BOT+BAL under the national protocol.
Significance for Patient Access
By extending fully reimbursed AAC access across colorectal cancer (搜索), ovarian cancer (搜索), and sarcoma, France has implemented a multi-tumor early access framework for a single investigational immunotherapy combination under one nationally standardized protocol. This represents an uncommon level of national early-access authorization and enables consistent hospital access to an investigational treatment while maintaining ANSM (搜索) oversight and structured patient follow-up as additional clinical and real-world evidence continues to develop.